What is Setmelanotide?
Setmelanotide (brand name IMCIVREE, formerly RM-493) is a selective agonist at the melanocortin-4 receptor (MC4R), a key node in the central nervous system circuit that regulates appetite and energy expenditure. It is the first and only approved drug that pharmacologically restores MC4R signaling in patients whose obesity is driven by upstream defects in the leptin–melanocortin pathway.
The MC4R pathway: leptin from adipose tissue activates POMC neurons in the hypothalamic arcuate nucleus, which release α-MSH, which binds MC4R on second-order neurons in the paraventricular nucleus, suppressing food intake and increasing thermogenesis. Loss-of-function mutations anywhere in this chain (POMC, PCSK1, LEPR, MC4R, BBS proteins) cause severe early-onset obesity with hyperphagia. Setmelanotide bypasses these upstream defects by directly activating MC4R.
Mechanism of Action
- Selective MC4R agonism — Setmelanotide is a cyclic 8-amino-acid peptide with high affinity for MC4R and minimal activity at MC1R/MC2R/MC3R/MC5R. (For comparison, the melanotans and PT-141 are non-selective melanocortin agonists with prominent MC1R/MC3R activity, which is why they cause skin pigmentation, sexual arousal, and erection — effects setmelanotide largely avoids.)
- Restored hypothalamic anorexigenic signaling — activation of MC4R in the paraventricular nucleus reduces hyperphagia and produces sustained weight loss.
- Increased energy expenditure — clinical pharmacology studies show modest but consistent increases in resting metabolic rate.
Clinical Evidence
Phase 3 trials in monogenic obesity (Lancet Diabetes & Endocrinology, 2020):
- POMC/PCSK1 deficiency (n=10): 80% achieved ≥10% weight loss at 1 year; mean weight loss 25.6 kg
- LEPR deficiency (n=11): 45% achieved ≥10% weight loss; mean weight loss 9.7 kg
- Hyperphagia scores improved markedly across both cohorts
Phase 3 in Bardet-Biedl syndrome (Lancet, 2022):
- 32% of patients ≥12 years achieved ≥10% weight loss at 52 weeks
- Reduction in hunger scores and BMI
TRANSCEND Phase 3 in acquired hypothalamic obesity (2026):
- Patients ages ≥4 with hypothalamic obesity from craniopharyngioma or related tumors
- FDA approval expanded to this indication in March 2026
Approval History
- November 27, 2020 — FDA approval for chronic weight management in adults and children ≥6 with POMC, PCSK1, or LEPR deficiency confirmed by genetic testing
- June 2022 — Bardet-Biedl syndrome added (ages ≥6)
- December 2024 — Pediatric expansion to ages ≥2 for BBS, POMC, and LEPR
- March 2026 — Acquired hypothalamic obesity (ages ≥4)
Distinction from Melanotans and PT-141
Setmelanotide is often confused with Melanotan I (afamelanotide), Melanotan II, and PT-141 (bremelanotide) because all four are melanocortin peptides. The differences:
| Peptide | MC1R | MC3R | MC4R | Use |
|---|---|---|---|---|
| Melanotan I | strong | yes | weak | skin pigmentation (EPP) |
| Melanotan II | strong | yes | yes | tanning (research) |
| PT-141 | weak | yes | strong | sexual arousal |
| Setmelanotide | minimal | minimal | strong | obesity (genetic) |
Setmelanotide's relative MC4R selectivity is what makes it suitable for chronic obesity treatment — it produces meaningful weight loss without the pigmentation, libido, or cardiovascular effects that limit other melanocortin peptides.
Safety and Side Effects
The most common adverse events are injection-site reactions, skin hyperpigmentation (despite MC4R selectivity, partial residual MC1R activity is seen), nausea, and headache. The label carries warnings for disturbances in sexual arousal, depression, and skin discoloration.
Setmelanotide is administered as a once-daily subcutaneous injection.